ArticleFood science & nutrition2025
Coffee Consumption and Risk of Incident Gastrointestinal Disease: A Large Prospective Cohort Study.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Coffee Consumption and Risk of Incident Gastrointestinal Disease: A Large Prospective Cohort Study.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coffee's health effects are well studied, but its relationship with gastrointestinal diseases (GIDs) remains unclear, particularly with the frequent use of sweeteners. A prospective cohort of 147,263 participants without pre-existing GIDs was analyzed. Coffee intake, assessed via a 24-h dietary recall, was categorized as unsweetened, naturally sweetened, or artificially sweetened. Incident GIDs were identified through medical records. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Genetic predisposition was assessed using polygenic risk scores (PRS), with subgroup and sensitivity analyses conducted for robustness. Over a 12.6-year median follow-up, 29,118 incident GIDs occurred. Unsweetened coffee showed a dose-dependent, U-shaped association with lower GID risk (P-non-linear < 0.001), with the lowest risk at 2-4 cups/day (HR: 0.84, 95% CI: 0.81-0.88). Naturally sweetened coffee had limited benefits, while artificial sweeteners showed inconsistent associations. Protective effects were observed for GERD, gastritis/duodenitis, and biliary diseases. Unsweetened coffee mitigated genetic GID risk, with significant additive interactions for diverticulosis and cirrhosis. Findings were robust across subgroup and sensitivity analyses. Unsweetened coffee consumption is associated with a lower GID risk, supporting its inclusion in dietary recommendations. Further studies are needed to clarify underlying mechanisms and validate findings in diverse populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.